Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Zepbound in Line for OSA Approval after Key Panel Nod
Eli Lilly’s obesity drug Zepbound (tirzepatide) cleared the review of a key health ministry panel on April 24 for an additional indication of obstructive sleep apnea (OSA), setting the stage for regulatory approval in Japan. The Pharmaceutical Affairs Council’s First…
To read the full story
Related Article
- Zepbound’s OSA Indication Up for Panel Review on April 24
April 20, 2026
REGULATORY
- H5N1 Pre-Pandemic Flu Vaccine Strain Re-Selected for FY2026 Stockpiling
April 27, 2026
- JIHS Inks MOU with German Network to Boost Infectious Disease Preparedness
April 27, 2026
- Govt Presents Draft Public-Private Investment Roadmap at Growth Strategy WG
April 27, 2026
- LDP Team Urges Patent-Period Price Maintenance, CEA Review in Growth Strategy Proposal
April 27, 2026
- Takaichi Says Govt to Weigh Response to MFN Drug Pricing Policy
April 27, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…